ARMI launches Strategy 2030: Transforming Health through Scientific Excellence 

The Australian Regenerative Medicine Institute (ARMI) today launched ​​Strategy 2030: Transforming Health through Scientific Excellence – a five-year strategic plan that sets the direction for Australia’s only dedicated regenerative medicine research institute, through to 2030. 

The strategy accelerates ARMI’s objective to progress regenerative medicine discoveries from the laboratory to the people who need them by scaling R&D pipelines across rare disease, musculoskeletal disease, diabetes, cardiovascular disease, neurodegeneration, dementia, infertility, ageing and spinal cord regeneration, and advancing therapeutics to first-in-human clinical trials. 

Strategy 2030 is structured around six pillars: 

• scientific excellence and impact
• regenerative medicine research and development at scale
• clinical translation of advanced therapies
• world-class education and development
• sustainability and operational excellence
• global leadership in regenerative medicine

Three measurable outcomes underpin the strategy: advancing a therapeutic through ARMI’s research pipelines to a first-in-human clinical trial; growing the institute’s PhD program to address the sector’s workforce shortage; and securing two major multi-investigator programmatic grants across different research themes. 

Professor ​​Peter Currie FAA IntFRSE, Director of Research at ARMI, said the strategy reflects a shift in how the institute operates – moving faster, working at greater scale and focusing more directly on delivery and outcomes.  

“We have already refined our approach. Now, we are accelerating it,” Professor Currie said. “Our globally respected scientific reputation, the highly integrated precinct we operate within, the ​​EMBL model we introduced to Australia that attracts exceptional talent from around the world, and the connected culture we actively nurture – inclusive, collaborative and driven by curiosity. These are the conditions that make everything else possible. 

“Strategy 2030 is about leveraging our firm foundations and channelling our energy to deepen our clinical translation pathways, expand our commercial capacity and propel our research and discoveries forward to reach the people we aim to help.” 

The strategy was developed following comprehensive consultation, including internal and external reviews of the institute in 2025, with the insights and recommendations made directly informing the final plan. 

Professor Currie said the timing was as much about readiness as it was about opportunity. 

“The previous strategy established the base we are now working from. We have the infrastructure, the partnerships and the research depth to move at pace with clear goals and laser-sharp focus. Strategy 2030 sets out how we will work together to achieve this and how we will translate our work into impactful outcomes for patients.” 

Strategy 2030 is aligned with Monash University’s Impact 2030 and the Monash Research and Enterprise Plan 2026–2028, and supports the Faculty of Medicine, Nursing and Health Sciences’ mission to improve human health. 

ARMI is one of the world’s largest regenerative medicine and stem cell research institutes, hosting 16 innovative research groups across musculoskeletal disease, diabetes, cardiovascular disease, neurodegeneration, rare disease, infertility, ageing and spinal cord degeneration. More than 200 staff and students from over 30 countries contribute to its research program – transforming health through scientific excellence.